Business
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early therapeutic ...
About this update from Pentixapharm Holding Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"First-in-human findings with [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer show early therapeutic activity, further validating CXCR4 as a clinically relevant target","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":322,"olType":false},{"type":"text","content":"BERLIN, DE / ACCESS Newswire / October 6, 2025 / Pentixapharm Holding AG (Frankfurt Prime Standard:PTP), an advanced clinical-stage biotech developing novel radiopharmaceuticals, today announced the presentation of extensive clinical data from independent investigator-initiated studies assessing Pentixapharm's CXCR4-targeting diagnostic lead candidate, [ 68 Ga]Ga-PentixaFor, at the ongoing Annual Congress of the European Association of Nuclear Medicine (EANM 2025) in Barcelona, Spain.","length":493,"tagName":"p"},{"type":"text","content":"At EANM 2025, four oral presentations and seven e-posters feature new data on [ 68 Ga]Ga-PentixaFor PET/CT imaging in Primary Aldosteronism (PA) - a condition frequently underdiagnosed despite being one of the leading causes of secondary hypertension. These presentations include comparative clinical trial results, evaluating [ 68 Ga]Ga-PentixaFor against adrenal venous sampling (AVS), the current invasive gold standard for subtyping PA. The data demonstrate the high potential of [ 68 Ga]Ga-PentixaFor to significantly improve subtyping of patients, thereby enabling better therapy decisions, and more precise patient management in PA.","length":639,"tagName":"p"},{"type":"text","content":"Complementing these results in cardiovascular and endocrine disease, the scientific program at EANM 2025 also showcases the expanding role of Pentixapharm's CXCR4-targeted platform in oncology. Among the highlights are first-in-human data on Pentixapharm's therapeutic candidate [¹⁷⁷Lu]Lu-PentixaTher, in patients with bladder cancer. The early findings demonstrate initial signs of therapeutic activity, adding to the growing body of evidence supporting [¹⁷⁷Lu]Lu-PentixaTher as a precision treatment candidate for CXCR4-positive malignancies.","length":552,"tagName":"p"},{...